China Cuts Prices for Cancer, Immune, Blood System Drugs

China cut the maximum retail prices for some cancer, immune and blood system drugs by an average of 17 percent, the country’s top planning agency said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.